{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/depression/management/ongoing-management/","result":{"pageContext":{"chapter":{"id":"0266ece8-500b-56bf-8e36-0d23273b3560","slug":"ongoing-management","fullItemName":"Scenario: Ongoing management","depth":2,"htmlHeader":"<!-- begin field 7bbb2f4f-caa3-490e-8e7c-a70700ff8b57 --><h2>Scenario: Ongoing management</h2><!-- end field 7bbb2f4f-caa3-490e-8e7c-a70700ff8b57 -->","summary":"Covers management of the review period, use of different interventions, the available and recommended treatment strategies, and how to minimize the risk of relapse.","htmlStringContent":"<!-- begin item 69fcf476-0b64-4c68-8c21-a70700ff8a2e --><!-- begin field f26560e9-d170-4316-929e-acd900ace257 --><p>From age 18 years onwards.</p><!-- end field f26560e9-d170-4316-929e-acd900ace257 --><!-- end item 69fcf476-0b64-4c68-8c21-a70700ff8a2e -->","topic":{"id":"5f794dff-eed8-52d6-bb65-1b1a9b1fc50a","topicId":"1b270734-f24e-4b58-8355-adaec350f356","topicName":"Depression","slug":"depression","lastRevised":"Last revised in February 2021","chapters":[{"id":"b34732f5-da05-5558-ac7e-4169aea1302d","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bd7d7dbf-c3a1-5690-8d7b-8fe76ab04a16","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"cd426153-dec3-52c5-a8ab-af99800c0ec3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"69de9fdc-1e49-5a89-8dc8-72e207b8e9d1","slug":"changes","fullItemName":"Changes"},{"id":"a3c07602-3d45-5287-8c9a-8f9efd7a336a","slug":"update","fullItemName":"Update"}]},{"id":"f87fe236-c4f0-50f8-b694-28b5778f138d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f1acf59a-ed11-5fb0-afc0-cee8532f5512","slug":"goals","fullItemName":"Goals"},{"id":"e98a7293-7a01-5fcc-9e1a-89b044ef1a02","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4182b8a5-9b8d-55e9-a4d9-fad2ca31d873","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"c55afa55-15bf-5a19-94a8-21ab0c17f7b7","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a6e7d7a8-fed0-5900-aab1-c863964e870a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"72e01363-0933-5668-b378-6249cb2b64f0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d36d2b88-dd20-5f53-882c-81e310273361","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"6358ea37-2401-503d-97aa-9d7fa8d3914d","slug":"definition","fullItemName":"Definition"},{"id":"d34c93b9-e882-588a-8711-b0acdcba167b","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f8f0d70d-670c-5aae-8508-7f5d3871c3ee","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"6b8dc395-d0cf-5820-9d98-cec770054a06","slug":"complications","fullItemName":"Complications"},{"id":"8ed2c15a-e56e-5667-9aa5-18c0957ec394","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"68029dcd-ffd8-58da-b515-711db2fe0564","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d4c125e5-95c8-5ac3-b5fa-10c5c9889c60","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"026c474a-d688-5999-a8bd-67dd4cb231c3","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"55c3f695-d02f-5148-bc68-ddbcddf71e3f","fullItemName":"Management","slug":"management","subChapters":[{"id":"a78bc764-d878-5441-b8d6-cbbcf394ce92","slug":"new-or-initial-management","fullItemName":"Scenario: New or initial management"},{"id":"0266ece8-500b-56bf-8e36-0d23273b3560","slug":"ongoing-management","fullItemName":"Scenario: Ongoing management"}]},{"id":"7355d977-542a-5e6a-9151-82ef7115fa94","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"5dce855c-f4fe-577d-8f55-2d88cdf3a9a4","slug":"dose-titration","fullItemName":"Dose and titration"},{"id":"1df758ad-1fe3-526c-bb06-f19414843379","slug":"switching-antidepressants","fullItemName":"Switching antidepressants"},{"id":"6f10b153-e084-5a21-ae48-3acb33411b10","slug":"toxicity-in-overdose","fullItemName":"Toxicity in overdose"},{"id":"0a0e189c-03e7-5c82-ba71-c96545755eeb","slug":"monitoring-antidepressants","fullItemName":"Monitoring antidepressants"},{"id":"f5deab35-56d4-5f9d-bc07-f29103e961ad","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding"},{"id":"f481ead9-8b60-571b-895e-d927223d993e","slug":"ssris","fullItemName":"SSRIs"},{"id":"83772b94-1512-51dd-99ad-a3fb7725267f","slug":"snris","fullItemName":"SNRIs"},{"id":"299a2937-fa9a-5b97-970b-a79af9a2fc00","slug":"tricyclic-antidepressants","fullItemName":"Tricyclic antidepressants"},{"id":"d4e99efd-b8fb-5453-9c75-f6382c8e25c5","slug":"mirtazapine","fullItemName":"Mirtazapine"},{"id":"3b9d10f7-2760-5bd9-bdf7-92f33416e2c9","slug":"moclobemide","fullItemName":"Moclobemide"},{"id":"823fe65c-0107-5657-8e8f-6ce91ed5cfb6","slug":"reboxetine","fullItemName":"Reboxetine"}]},{"id":"725ab0c0-f1a9-5756-833a-ea5c4f8721bf","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"17b06435-7e75-56bf-80c0-57858b6db92c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7eeea9f4-7f32-515a-b661-5f51a513cba7","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3907465f-bd0e-530a-b486-c2655ccaba7c","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"6cef4cda-5622-50b2-9759-9e03266800d3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"59840e87-e4f4-5c49-a6f1-f67d210f3dc0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7d357e2c-3884-5b0c-b9a3-bbf7420da7a9","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3a86a38c-4d81-57f0-ac72-7b5260328853","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"55c3f695-d02f-5148-bc68-ddbcddf71e3f","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"6731247c-6e99-5e2b-9767-37014cc63f0a","slug":"assessment","fullItemName":"Assessment","depth":3,"htmlHeader":"<!-- begin field 53ee6ff0-9056-4a16-9c0d-a70700ff8b57 --><h3>How should I assess someone at review?</h3><!-- end field 53ee6ff0-9056-4a16-9c0d-a70700ff8b57 -->","summary":null,"htmlStringContent":"<!-- begin item 83f212eb-5e28-4a79-a4d7-a70700ff8b57 --><!-- begin field a3d3245c-97ca-4558-89ac-a70700ff8b57 --><ul><li>Reassess:<ul><li><strong>The <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/new-or-initial-management/#assessing-risk-of-suicide\">risk of suicide</a>.</strong></li><li><strong>Any safeguarding concerns if appropriate.</strong></li><li><strong>The person's depressive symptoms</strong> and response to any treatments that may have been started. <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/new-or-initial-management/#depression-questionnaires\">Depression questionnaires</a> may be useful to monitor the person's progress.</li><li><strong>Factors which may affect the development, course and severity of depression, including: </strong><ul><li>The quality of interpersonal relationships.</li><li>Living conditions and social isolation.</li><li>Employment and immigration status.</li><li>Availability of social support.</li></ul></li><li><strong>Assess the benefits of any <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/new-or-initial-management/#psychosocial-psychological-interventions\">psychological interventions</a>.</strong></li><li><strong>Enquire about adverse effects of antidepressants and adherence to treatment.</strong></li></ul></li></ul><!-- end field a3d3245c-97ca-4558-89ac-a70700ff8b57 --><!-- end item 83f212eb-5e28-4a79-a4d7-a70700ff8b57 -->","subChapters":[{"id":"5726dfa4-6d1c-5f08-83a2-21a3f5069ee9","slug":"basis-for-recommendation-fe6","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 2f9c0466-c0de-4f94-ae47-a70700ff8b5b --><h4>Basis for recommendation</h4><!-- end field 2f9c0466-c0de-4f94-ae47-a70700ff8b5b -->","summary":null,"htmlStringContent":"<!-- begin item fe672c6b-2382-480a-b92f-a70700ff8b5b --><!-- begin field c931321a-9150-49f4-b345-a70700ff8b5b --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Depression: the treatment and management of depression in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2019</a>] and <em>Depression in adults with a chronic physical health problem </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2009</a>], and the British Association for Psychopharmacology<em> Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Cleare, 2015</a>].</p><!-- end field c931321a-9150-49f4-b345-a70700ff8b5b --><!-- end item fe672c6b-2382-480a-b92f-a70700ff8b5b -->","subChapters":[]}]},{"id":"bd57c711-4efd-5df3-bc25-190ecd06612a","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field f7e6106e-1f47-4c8e-a315-a707010090fd --><h3>What ongoing management is required?</h3><!-- end field f7e6106e-1f47-4c8e-a315-a707010090fd -->","summary":null,"htmlStringContent":"<!-- begin item baf0459b-8dde-4c93-9aa0-a70701008fea --><!-- begin field 546a4bf8-f6d2-437d-aedd-a707010090fd --><ul><li><strong>Manage suicide risk</strong>. Options include:<ul><li>Contacting the <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/new-or-initial-management/#crisis-services\">Crisis Resolution and Home Treatment (CRHT) team</a> for an urgent assessment. Voluntary admission or <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/new-or-initial-management/#compulsory-admission\">Compulsory admission</a> may be required.</li><li>Reviewing a person frequently in primary care.</li></ul></li><li><strong>Manage any ongoing safeguarding concerns</strong> and follow local safeguarding procedures if appropriate.</li><li><strong>If there has been a poor response to treatment:</strong><ul><li><strong>For people with subthreshold depressive symptoms or mild-to-moderate depression who: </strong><ul><li>Are still unwell after 2 weeks of active monitoring, consider a <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/new-or-initial-management/#psychosocial-psychological-interventions\">low-intensity psychosocial intervention</a>. This is accessed by referral or self-referral to Improving access to Psychological Therapies (IAPT).</li><li>Have failed to respond to a low-intensity psychosocial intervention, consider an <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/new-or-initial-management/#choosing-an-antidepressant\">antidepressant</a>, or a <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/new-or-initial-management/#psychosocial-psychological-interventions\">high-intensity psychological intervention</a>.</li><li>Are already taking an antidepressant, check adherence, manage any <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/ongoing-management/#managing-antidepressants-adverse-effects\">adverse effects</a> and consider <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/ongoing-management/#altering-antidepressant-treatment\">altering antidepressant</a> treatment (either increasing the dose or changing drug). For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/ongoing-management/#switching-antidepressants\">switching antidepressants</a>. </li></ul></li><li><strong>For people with moderate or severe depression who have not responded to initial treatment</strong><strong>: </strong><ul><li>Consider combination therapy with an antidepressant and a high-intensity psychological intervention (if this has not already been tried). </li><li>If the person is already taking an antidepressant, check adherence, manage any adverse effects and consider altering antidepressant treatment (either increasing the dose or changing the drug ). For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/ongoing-management/#switching-antidepressants\">switching antidepressants</a>. </li><li>If the depression is complex and severe, refer to specialist services.</li><li><strong>For people who also have a chronic physical health problem,</strong> consider referral to a psychiatrist and a physician of the appropriate speciality for collaborative care. </li></ul></li></ul></li><li><strong>For people having difficulty sleeping</strong>, offer sleep hygiene advice. For more information, see the <a class=\"topic-reference external-reference\" href=\"/topics/insomnia/management/managing-short-term-insomnia-less-3-months/#good-sleep-hygiene\">Good sleep hygiene</a> section in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/insomnia/\">Insomnia</a>. </li><li><strong>Arrange regular <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/ongoing-management/#follow-up\">follow up</a> </strong>to assess the response to treatment, the need for further management, and for any adverse effects or compliance issues associated with taking anti-depressants.</li><li><strong>Provide <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/new-or-initial-management/#information-advice\">information and advice</a> </strong>about depression and its treatment. Advise the person not to use St John's wort.</li></ul><!-- end field 546a4bf8-f6d2-437d-aedd-a707010090fd --><!-- end item baf0459b-8dde-4c93-9aa0-a70701008fea -->","subChapters":[{"id":"86cedf6d-82e8-5d0c-a106-ed9e60698707","slug":"psychological-interventions","fullItemName":"Psychological interventions","depth":4,"htmlHeader":"<!-- begin field 0a0fead2-6e81-49ad-b7b1-a7a701226e5b --><h4>Psychological interventions</h4><!-- end field 0a0fead2-6e81-49ad-b7b1-a7a701226e5b -->","summary":null,"htmlStringContent":"<!-- begin item 1355c4aa-207f-41bc-b980-a7a701226bf1 --><!-- begin field 473d8098-a51c-4a46-be2e-a7a701226e5b --><ul><li><strong>In addition to other <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/new-or-initial-management/#psychosocial-psychological-interventions\">Psychosocial and psychological interventions</a>, mindfulness-based cognitive therapy may be used for people who are currently well but have experienced three or more previous episodes of depression. </strong><ul><li>This is a group based skills programme that is usually provided in 8 group sessions.</li><li>It enables people to learn to recognize early warning signs in terms of negative bodily sensations, thoughts, and feelings, and to develop constructive responses that prevent relapse.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2019</a>]</p><!-- end field 473d8098-a51c-4a46-be2e-a7a701226e5b --><!-- end item 1355c4aa-207f-41bc-b980-a7a701226bf1 -->","subChapters":[]},{"id":"5d8edfa6-4f50-5c66-8203-60153b5e56d5","slug":"managing-antidepressants-adverse-effects","fullItemName":"Managing antidepressants adverse effects","depth":4,"htmlHeader":"<!-- begin field a837afb9-92ed-478f-a681-a7a70121aca3 --><h4>Managing antidepressants adverse effects</h4><!-- end field a837afb9-92ed-478f-a681-a7a70121aca3 -->","summary":null,"htmlStringContent":"<!-- begin item 52cc2bbd-d846-4b1a-9363-a7a70121a9f7 --><!-- begin field d401d27c-4e55-4b04-8bcf-a7a70121aca3 --><ul><li><strong>Suicidal thoughts and suicide attempts</strong> — all antidepressants have been associated with an increase in suicidal thoughts and suicide attempts in adolescents and young adults, and people with a history of suicidal behaviour. The absolute risk is thought to be very small, however people who have higher risk should be monitored for suicidal behaviour, self-harm, or hostility, particularly at the beginning of treatment or if the dose is changed.</li><li><strong>Anxiety, agitation, or insomnia</strong> — if these are problematic, consider short-term (usually less than 2 weeks) concomitant treatment with a benzodiazepine. </li><li><strong>Hyponatraemia</strong> — this can occur with all antidepressants, although the highest risk is with selective serotonin reuptake inhibitors (SSRIs). The onset is usually within 30 days of starting treatment, but occasionally may take many months. Rapid onset may also occur in the first few days of treatment.<ul><li>Consider hyponatraemia if the person develops dizziness, drowsiness, confusion, nausea, muscle cramps, or seizures. </li><li>If hyponatraemia is suspected, stop the antidepressant and manage according to the severity and duration of symptoms, and state of hydration. <ul><li>After serum sodium levels have normalised, choose another appropriate antidepressant.</li></ul></li><li>Risk factors for hyponatraemia include: <ul><li>Older age.</li><li>Female gender.</li><li>Major surgery.</li><li>History of hyponatraemia or a low baseline sodium concentration.</li><li>Co‐therapy with other drugs known to be associated with hyponatraemia (for example, diuretics, NSAIDs, antipsychotics, carbamazepine, cancer chemotherapy, calcium antagonists, angiotensin‐converting enzyme inhibitors and laxatives).</li><li>Reduced renal function (glomerular filtration rate [GFR] <50 mL/min).</li><li>Medical comorbidity (for example, hypothyroidism, diabetes, chronic obstructive pulmonary disease, hypertension, head injury, congestive cardiac failure, cerebrovascular accident, various cancers)</li><li>Low body weight.</li></ul></li></ul></li><li><strong>Sexual dysfunction</strong> — sexual dysfunction is a common symptom of depression, all antidepressants can cause sexual dysfunction (for example, decreased libido, erectile dysfunction, delayed orgasm, impaired ejaculation) to varying degrees (most commonly serotonin reuptake inhibitors). Treatment options include:<ul><li>A period of watchful waiting (spontaneous remission occurs in 5–10% of people).</li><li>Reducing the dose of the antidepressant for people who have achieved full remission.</li><li>Drug holidays —intermittently missing one or two doses prior to planned sexual activity (this is not effective with fluoxetine due to its long half-life).</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/depression/prescribing-information/switching-antidepressants/\">Switching antidepressants</a> to an antidepressant which is less likely to cause the specific problem (for example, mirtazapine, or moclobemide).</li><li>Adjunctive treatment with a phosphodiesterase inhibitor (such as sildenafil) for erectile dysfunction. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/erectile-dysfunction/\">Erectile dysfunction</a>.</li><li><strong>Persistent, severe, or distressing adverse effects may be managed by:</strong> <ul><li>Dose reduction and re-titration (if possible).</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/ongoing-management/#switching-antidepressants\">Switching antidepressants</a> to an antidepressant less likely to cause that adverse effect.</li></ul></li><li><strong>Mild and transient adverse effects </strong>such as nausea induced by SSRIs may be managed by explanation, reassurance and, if necessary, dose reduction and re-titration. </li><li><strong>For detailed information on adverse effects of antidepressants see the information for individual drugs in the section on <a class=\"topic-reference internal-reference\" href=\"/topics/depression/prescribing-information/\">Prescribing information</a>. </strong></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">MHRA, 2014b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Cleare, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">SPS, 2019b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Taylor, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2019</a>]</p><style type=\"text/css\">//<![CDATA[//<![CDATA[//<![CDATA[//<![CDATA[//<![CDATA[//]]>////]]>////]]>////]]>////]]>//</style></li></ul><!-- end field d401d27c-4e55-4b04-8bcf-a7a70121aca3 --><!-- end item 52cc2bbd-d846-4b1a-9363-a7a70121a9f7 -->","subChapters":[]},{"id":"44676a39-8b42-5bc3-b7a9-3ab3108e0aee","slug":"basis-for-recommendation-626","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field dda5fb47-d982-460f-b564-a70701009101 --><h4>Basis for recommendation</h4><!-- end field dda5fb47-d982-460f-b564-a70701009101 -->","summary":null,"htmlStringContent":"<!-- begin item 6263fdaf-9313-4dc6-8015-a70701009101 --><!-- begin field 11e544cc-6192-45b2-bc54-a70701009101 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Depression: the treatment and management of depression in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2019</a>] and <em>Depression in adults with a chronic physical health problem </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2009</a>].</p><style type=\"text/css\"></style><!-- end field 11e544cc-6192-45b2-bc54-a70701009101 --><!-- end item 6263fdaf-9313-4dc6-8015-a70701009101 -->","subChapters":[]}]},{"id":"3288b1d1-0dd5-54f8-b000-f5b0601a8610","slug":"follow-up","fullItemName":"Follow up","depth":3,"htmlHeader":"<!-- begin field 975c2987-a221-4f73-8752-a7070100a6c0 --><h3>What ongoing follow-up is required?</h3><!-- end field 975c2987-a221-4f73-8752-a7070100a6c0 -->","summary":null,"htmlStringContent":"<!-- begin item 326f3da7-5726-4c7a-be46-a7070100a5a7 --><!-- begin field e1df92f7-790c-496e-874b-a7070100a6c0 --><ul><li><strong>The review period should be determined by:</strong><ul><li>The risk of suicide.</li><li>The need to assess the tolerability and effectiveness of any treatments started or changed.</li></ul></li><li><strong>In general, for people not considered to be at an increased risk of suicide</strong> arrange reviews every 2–4 weeks for the first 3 months then longer intervals if the response to treatment is good. </li><li><strong>Support and encourage people who have benefitted from taking an antidepressant to continue it for at least 6 months after remission. </strong>Advise the person that: <ul><li>This greatly reduces the risk of relapse.</li><li>Antidepressants are not associated with addiction. </li></ul></li><li><strong>Review the need to continue treatment beyond 6 months, taking into account: </strong><ul><li>The number of previous episodes of depression.</li><li>The presence of residual symptoms.</li><li>Ongoing physical health problems and psychosocial difficulties.</li></ul></li><li><strong>For people at significant risk of relapse or those with a history of recurrent depression, discuss treatments to reduce the risk of recurrence including: </strong><ul><li>Continuing medication.</li><li>Augmentation of medication — combinations of medicines should only be started in consultation with a psychiatrist.</li><li>Augmentation of psychological treatment.</li></ul></li><li><strong>Advise people at risk of relapse to continue </strong><strong>treatment for at least 2 years,</strong> maintained at the effective treatment dose, if: <ul><li>They have had two or more episodes of depression in the recent past during which they experienced functional impairment.</li><li>If they have other risk factors for relapse such as residual symptoms, multiple episodes, or a history of severe or prolonged episodes or inadequate response.</li><li>The consequences of relapse are likely to be severe (for example, suicide attempts, loss of functioning, severe life disruption, and inability to work).</li></ul></li><li><strong>Re-evaluate people after 2 years to decide whether to continue treatment</strong>. Take into account:<ul><li>The person's age.</li><li>Comorbid conditions.</li><li>Other risk factors. </li></ul></li><li><strong>Regularly re-evaluate people on long-term maintenance treatment</strong>. Take into account:<ul><li>Comorbid conditions.</li><li>Risk factors for relapse.</li><li>Severity and frequency of episodes of depression.</li></ul></li><li><strong>Consider psychological interventions to prevent relapse including:</strong> <ul><li>Individual cognitive behavioural therapy.</li><li>Mindfulness-based cognitive therapy.</li></ul></li><li><strong>Consider additional social support</strong> including: <ul><li>Befriending (where trained volunteers provide at least weekly contact for 2–6 months).</li><li>A rehabilitation programme (particularly if there has been long-term loss of work or social disengagement).</li></ul></li></ul><!-- end field e1df92f7-790c-496e-874b-a7070100a6c0 --><!-- end item 326f3da7-5726-4c7a-be46-a7070100a5a7 -->","subChapters":[{"id":"5e142e59-29d2-5251-a05a-8ce91edad126","slug":"basis-for-recommendation-737","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d37d3bbe-8825-4cf0-b8a9-a7070100a6c4 --><h4>Basis for recommendation</h4><!-- end field d37d3bbe-8825-4cf0-b8a9-a7070100a6c4 -->","summary":null,"htmlStringContent":"<!-- begin item 737f3501-c9c9-448c-9c5d-a7070100a6c4 --><!-- begin field 5c8cbb75-da88-470b-a870-a7070100a6c4 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Depression: the treatment and management of depression in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2019</a>].</p><!-- end field 5c8cbb75-da88-470b-a870-a7070100a6c4 --><!-- end item 737f3501-c9c9-448c-9c5d-a7070100a6c4 -->","subChapters":[]}]},{"id":"60149874-5975-55da-9f84-09faa0a91d9a","slug":"altering-antidepressant-treatment","fullItemName":"Altering antidepressant treatment","depth":3,"htmlHeader":"<!-- begin field d10f0850-5aa2-4a9b-86ad-a7070100dbf7 --><h3>When and how should I alter antidepressant treatment?</h3><!-- end field d10f0850-5aa2-4a9b-86ad-a7070100dbf7 -->","summary":null,"htmlStringContent":"<!-- begin item 94625ffc-db5f-4863-a9a7-a7070100da0b --><!-- begin field 85e8f794-dde6-40c7-95a9-a7070100dbf7 --><ul><li><strong>In general, an antidepressant effect is usually seen within 2 weeks of starting treatment.</strong></li><li><strong>If no effect is seen after 2–4 weeks,</strong> check adherence and enquire about adverse effects. </li><li><strong>If </strong><strong>response</strong><strong> is absent or minimal after 3–4 weeks of treatment with a therapeutic dose of an antidepressant, </strong>consider:<ul><li>Increasing the dose in line with product recommendations (if there are no significant adverse effects), or </li><li><a class=\"topic-reference internal-reference\" href=\"/topics/depression/prescribing-information/switching-antidepressants/\">Switching antidepressants</a> to a selective serotonin reuptake inhibitor (SSRI) if the person is not already taking one, or to a different SSRI. </li><li>Switching antidepressants to a different class of antidepressant; for example if an SSRI has been used initially, switch to a tricyclic antidepressant (TCA) such as amitriptyline. Other reasonable choices include lofepramine, trazodone, and venlafaxine. </li></ul></li><li><strong>If there is some response by 4 weeks</strong>, continue the antidepressant for another 2–4 weeks and check for adequate response.</li><li><strong>If the response is inadequate at 6–8 weeks,</strong> there are adverse effects, or the person prefers to change treatment, consider switching to a different antidepressant. </li><li><strong>When switching antidepressants,</strong> consider:<ul><li>Any comorbid conditions or potential drug interactions that may influence choice of drug (see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/new-or-initial-management/#chronic-physical-health-problems\">chronic physical health problems</a>).</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/ongoing-management/#managing-antidepressants-adverse-effects\">Adverse effects</a> profile — for example sedation, sexual adverse effects, weight gain.</li><li>The risk of serotonin syndrome — this can occur when combinations of serotonergic antidepressants are prescribed, and so care is needed when switching. Features of serotonin syndrome include confusion, delirium, shivering, sweating, changes in blood pressure and myoclonus.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/depression/prescribing-information/toxicity-in-overdose/\">Toxicity in overdose</a> — if there is a history or likelihood of overdose, avoid venlafaxine and TCAs. </li></ul></li><li><strong>At any stage of treatment, the antidepressant can be stopped if the person has unacceptable adverse effects or if the person prefers.</strong><ul><li>In general, when stopping an antidepressant, reduce the dose or frequency gradually over a 4-week period. This minimizes discontinuation symptoms. For detailed information on how to stop antidepressants, see <a class=\"topic-reference internal-reference\" href=\"/topics/depression/management/ongoing-management/#stopping-antidepressants\">Stopping antidepressants</a>. </li></ul></li></ul><!-- end field 85e8f794-dde6-40c7-95a9-a7070100dbf7 --><!-- end item 94625ffc-db5f-4863-a9a7-a7070100da0b -->","subChapters":[{"id":"e758bdde-4003-50f3-a395-0e1c4d56b0e9","slug":"basis-for-recommendation-b72","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 09d02a71-d8e0-4771-99bd-a7070100dbfa --><h4>Basis for recommendation</h4><!-- end field 09d02a71-d8e0-4771-99bd-a7070100dbfa -->","summary":null,"htmlStringContent":"<!-- begin item b72ca21b-f337-4f34-a5b5-a7070100dbfa --><!-- begin field 9cdaa1d8-c73f-4ec5-8040-a7070100dbfa --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Depression: the treatment and management of depression in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2019</a>] and <em>Depression in adults with a chronic physical health problem </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2009</a>].</p><p><strong>Increasing the dose of an antidepressant </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2019</a>]</p><ul><li>NICE states that the evidence for increasing the dose of an antidepressant (if the person has not responded adequately to a standard dose) is not convincing. However, it concludes that overall this strategy may be effective in some people, especially if they have been able to tolerate the antidepressant at the initial dose.</li></ul><p><strong>Switching to a different antidepressant </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2019</a>]</p><ul><li>The evidence for switching to another antidepressant is stronger than that for increasing the dose of the antidepressant, although the evidence for the relative advantage of switching either within or between classes is weak and there is insufficient robust evidence about which antidepressant to switch to. </li><li>Overall, switching is likely to be a worthwhile strategy, and data from primary efficacy head-to-head studies suggest that venlafaxine and escitalopram may offer marginal benefits over other antidepressants.  </li><li>Choice of antidepressant should be guided by similar principles to that of choosing an initial antidepressant (for example adverse effect profile, drug interactions, the person's preference).</li></ul><style type=\"text/css\"></style><!-- end field 9cdaa1d8-c73f-4ec5-8040-a7070100dbfa --><!-- end item b72ca21b-f337-4f34-a5b5-a7070100dbfa -->","subChapters":[]}]},{"id":"ddd8fb03-7998-5754-86df-ec4fefa827fe","slug":"switching-antidepressants","fullItemName":"Switching antidepressants","depth":3,"htmlHeader":"<!-- begin field 2e9e8d4f-bfd2-4d66-be8d-ab250123ddb6 --><h3>How should I manage switching of antidepressants?</h3><!-- end field 2e9e8d4f-bfd2-4d66-be8d-ab250123ddb6 -->","summary":null,"htmlStringContent":"<!-- begin item b90a850f-eb6a-47a2-a77a-ab250123dd8f --><!-- begin field 89d7d9c4-1713-4334-a981-ab250123ddb6 --><ul><li>Abrupt withdrawal should generally be avoided when switching from one antidepressant to another. </li><li>Cross tapering is usually preferred and should be done cautiously (an example of a cross-tapering regimen is shown in Table 1) — it involves gradually reducing the dose of the first antidepressant while starting the second antidepressant at a low dose and then gradually increasing this dose as the first drug is withdrawn.<ul><li>The example shows a weekly schedule, however for some people the schedule may need to be fortnightly or longer.</li><li>People should be monitored for tolerability when switching. </li></ul></li><li>In some instances it may be possible to withdraw the current antidepressant and start the new antidepressant the next day, for example when switching from one selective serotonin reuptake inhibitor (SSRI) to another SSRI or a serotonin noradrenaline reuptake inhibitor (SNRI) — the exception to this is fluoxetine.</li><li>Cross-tapering a tricyclic antidepressant (TCA) with paroxetine or fluvoxamine is inadvisable — if necessary it should be done very cautiously [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">SPS, 2019c</a>].  </li><li>Clomipramine is a potent inhibitor of serotonin reuptake and serotonin syndrome is more likely if co-administered with an SSRI or SNRI — cross-tapering is not recommended except under specialist supervision [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">SPS, 2019c</a>].  <ul><li>Clomipramine should be withdrawn before starting an SSRI or SNRI. Similarly, if switching from an SSRI or SNRI to clomipramine these medications should be stopped before starting clomipramine.</li></ul></li><li>Be aware that interactions with fluoxetine may still occur for 5 weeks after stopping fluoxetine because of its long half-life.</li><li>See Table 2 for information on how to manage switching between antidepressants.</li></ul><p><br><strong>Table 1.</strong> An example of a cross-tapering regimen — switching from citalopram to mirtazapine.</p><table data-table-id=\"d68eb32e-c7dd-4118-90be-acce014f8dc8\"><thead><tr><th scope=\"col\"> </th><th scope=\"col\">Pre-switch dosage</th><th scope=\"col\">Week 1</th><th scope=\"col\">Week 2</th><th scope=\"col\">Week 3</th><th scope=\"col\">Week 4</th></tr></thead><tbody><tr><td><strong>Withdrawing citalopram</strong></td><td>40 mg daily</td><td>20 mg daily</td><td>10 mg daily</td><td>nil</td><td>nil</td></tr><tr><td><strong>Introducing mirtazapine</strong></td><td>Nil</td><td>15 mg daily</td><td>30 mg daily</td><td>30 mg daily</td><td>45 mg daily (if required)</td></tr><tr><td colspan=\"6\"><strong>Data from: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Taylor, 2018</a>]</td></tr></tbody></table><p><br><strong>Table 2. </strong>Switching antidepressants.</p><table data-table-id=\"14c67832-98ba-4edc-824f-acce014f8dc8\"><thead><tr><th scope=\"col\"> </th><th colspan=\"8\" rowspan=\"1\" scope=\"col\">Switching to:</th></tr><tr><th scope=\"col\">Switching from:</th><th scope=\"col\"> TCA (except clomipramine)</th><th scope=\"col\">SSRI (citalopram, escitalopram, paroxetine or sertraline)</th><th scope=\"col\">SNRI (duloxetine, venlafaxine)</th><th scope=\"col\">Fluoxetine</th><th scope=\"col\">Mirtazapine</th><th scope=\"col\">Moclobemide</th><th scope=\"col\">Reboxetine</th><th scope=\"col\">Trazodone</th></tr></thead><tbody><tr><td> TCA (except clomipramine)</td><td>Direct switch possible</td><td><p>Gradually reduce the dose of TCA to 25–50 mg daily [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">SPS, 2019c</a>] or half the usual dose [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Taylor, 2018</a>]. Start SSRI then slowly withdraw TCA over next 5–7 days [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">SPS, 2019c</a>]</p></td><td>Cross-taper cautiously starting with low dose SNRI</td><td>Halve dose of TCA, add fluoxetine and then slowly withdraw TCA</td><td>Cross-taper cautiously</td><td>Taper then stop TCA, then wait for 1 week then start moclobemide</td><td>Cross-taper cautiously</td><td>Halve dose of TCA, add trazodone and then slowly withdraw TCA</td></tr><tr><td>SSRIs (citalopram, escitalopram, paroxetine or sertraline)</td><td><p>Cross-taper cautiously with low dose of TCA</p></td><td>Direct switch possible</td><td>Direct switch possible (caution if paroxetine used)</td><td>Direct switch possible</td><td>Cross-taper cautiously</td><td>Taper then stop SSRI, wait for 1 week then start moclobemide</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td></tr><tr><td>SNRIs (duloxetine, venlafaxine)</td><td>Cross-taper cautiously with low dose of TCA</td><td>Direct switch possible</td><td>Direct switch possible</td><td>Direct switch possible</td><td>Cross-taper cautiously</td><td>Taper then stop SNRI, wait for 1 week then start moclobemide</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td></tr><tr><td>Fluoxetine</td><td>Stop fluoxetine, start TCA at a low dose 4–7 days later and increase dose very slowly</td><td>Stop fluoxetine, start SSRI at a low dose 4–7 days later</td><td>Stop fluoxetine, start SSRI at a low dose 4–7 days later</td><td>—</td><td>Cross-taper cautiously</td><td>Stop fluoxetine then wait for 5–6 weeks then start moclobemide</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td></tr><tr><td>Mirtazapine</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td><td>—</td><td>Taper then stop mirtazapine, wait for 1 week then start moclobemide</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td></tr><tr><td>Moclobemide</td><td>Taper moclobemide then stop, then wait 24 hours before starting the other antidepressant</td><td>Taper moclobemide then stop, then wait 24 hours before starting the other antidepressant</td><td>Taper moclobemide then stop, then wait 24 hours before starting the other antidepressant</td><td>Taper moclobemide then stop, then wait 24 hours before starting the other antidepressant</td><td>Taper moclobemide then stop, then wait 24 hours before starting the other antidepressant</td><td>—</td><td>Taper moclobemide then stop, then wait 24 hours before starting the other antidepressant</td><td>Taper moclobemide then stop, then wait 24 hours before starting the other antidepressant</td></tr><tr><td>Reboxetine</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td><td>Taper then stop reboxetine, wait for 1 week then start moclobemide</td><td>—</td><td>Cross-taper cautiously</td></tr><tr><td>Trazodone</td><td>Cross-taper cautiously with low dose of TCA</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td><td>Cross-taper cautiously</td><td>Taper then stop trazodone, wait for 1 week then start moclobemide</td><td>Cross-taper cautiously</td><td>—</td></tr><tr><td colspan=\"9\"><strong>Sources: </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Taylor, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">SPS, 2019c</a>]</td></tr></tbody></table><!-- end field 89d7d9c4-1713-4334-a981-ab250123ddb6 --><!-- end item b90a850f-eb6a-47a2-a77a-ab250123dd8f -->","subChapters":[{"id":"6a2fda89-51ed-5a04-88d7-ccfdd34d4823","slug":"basis-for-recommendation-221","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 85a0b942-731a-4c11-b44d-ab250123ddb8 --><h4>Basis for recommendation</h4><!-- end field 85a0b942-731a-4c11-b44d-ab250123ddb8 -->","summary":null,"htmlStringContent":"<!-- begin item 2217da2e-882b-4224-b8ec-ab250123ddb8 --><!-- begin field 63da7cbd-0daa-40ab-b1ca-ab250123ddb8 --><p>These recommendations are based on a medical textbook <em>The Maudsley prescribing guidelines in psychiatry</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Taylor, 2018</a>], and the Specialist Pharmacy Service (SPS) document <em>How do you switch between tricyclic, SSRI and related antidepressants? </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">SPS, 2019c</a>].</p><!-- end field 63da7cbd-0daa-40ab-b1ca-ab250123ddb8 --><!-- end item 2217da2e-882b-4224-b8ec-ab250123ddb8 -->","subChapters":[]}]},{"id":"59c8fb1a-db0d-51ef-98ae-b55fe81652d0","slug":"stopping-antidepressants","fullItemName":"Stopping antidepressants","depth":3,"htmlHeader":"<!-- begin field 2ada6530-293e-4be2-8c11-ab2501148759 --><h3>How should antidepressants be stopped?</h3><!-- end field 2ada6530-293e-4be2-8c11-ab2501148759 -->","summary":null,"htmlStringContent":"<!-- begin item 0ab09f91-14c2-469d-8d9b-ab2501148722 --><!-- begin field 95186f97-f7cb-47df-b0bd-ab2501148759 --><ul><li><strong>In general, reduce the dose or frequency of the antidepressant gradually over a 4-week period</strong> to minimize discontinuation symptoms. <ul><li>Discontinuation symptoms may occur when stopping or reducing the dose of any antidepressant, and include: restlessness, problems sleeping, unsteadiness, sweating, abdominal symptoms, altered sensations (electric shock feelings, paraesthesiae), altered feelings (for example irritability, anxiety, confusion), anxiety, confusion, lethargy, headache.</li><li>Onset is usually within a few days of stopping treatment. </li><li>Symptoms are mild, self-limiting and of short duration (usually lasting 1–2 weeks). However, occasionally they can be severe and last for weeks.</li><li>Discontinuation symptoms are more common with higher doses, longer treatment courses (up to 9 weeks when it plateaus), and rarely occur with treatments lasting less than 8 weeks. </li><li>Discontinuation symptoms are more likely with antidepressants with a short half-life (such as paroxetine or venlafaxine).</li></ul></li><li><strong>A shorter or longer tapering period may be required for people</strong>:<ul><li>With severe adverse reactions to treatment (for example cardiac arrhythmia with a tricyclic antidepressant) — a more rapid (abrupt) discontinuation may be necessary. </li><li>Who have been receiving longer-term maintenance treatment — a period of months may be required. </li><li>Taking fluoxetine — treatment can be stopped abruptly at a dose of 20 mg because fluoxetine has a long half-life and active metabolites. However, people taking higher doses may require gradual withdrawal over 2 weeks. </li></ul></li><li>Slow tapering may not always reduce the incidence or severity of discontinuation reactions. Some people may prefer abrupt cessation and a shorter discontinuation syndrome. However, abrupt stopping of antidepressants probably increases the risk of relapse. </li><li>Advise the person to seek advice if they experience significant discontinuation symptoms. </li><li>If discontinuation symptoms are mild, reassure the person that they will pass in a few days — this is often all that is required.</li><li>If discontinuation symptoms are severe, consider reintroducing the original antidepressant at a dose not associated with discontinuation symptoms (or another antidepressant with a longer half-life from the same class) and then taper more slowly while monitoring symptoms. </li></ul><!-- end field 95186f97-f7cb-47df-b0bd-ab2501148759 --><!-- end item 0ab09f91-14c2-469d-8d9b-ab2501148722 -->","subChapters":[{"id":"b8afd2c1-eb31-522b-8a7e-685006837d6a","slug":"basis-for-recommendation-de5","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 4954ee4d-5905-4cdb-9516-ab250114875c --><h4>Basis for recommendation</h4><!-- end field 4954ee4d-5905-4cdb-9516-ab250114875c -->","summary":null,"htmlStringContent":"<!-- begin item de58d55d-f18a-42e7-8ddd-ab250114875c --><!-- begin field 80d8760f-3dbe-405d-954c-ab250114875c --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Depression: the treatment and management of depression in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">National Collaborating Centre for Mental Health, 2019</a>], the British Association for Psychopharmacology<em> Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Cleare, 2015</a>], and a medical textbook <em>The Maudsley prescribing guidelines in psychiatry</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression/references/\">Taylor, 2018</a>].   </p><!-- end field 80d8760f-3dbe-405d-954c-ab250114875c --><!-- end item de58d55d-f18a-42e7-8ddd-ab250114875c -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}